OARSI 2016: Potential benefit of Wnt inhibitor, SM04690, in moderate to severe knee OA .
Omeract-oarsi ‘strict responders’ analysis from results of a randomized, double-blind, placebo-controlled phase 1 study of a novel, intra-articular, injectable, wnt inhibitor (sm04690) in the treatment of osteoarthritis of the knee
61 patients with moderate to severe osteoarthritis of the knee were included in this study and randomized to undergo treatment with an intra-articular injection of 0.03mg, 0.07mg, or 0.23 mg of a Wnt pathway inhibitor molecule, SM04690, or a placebo. The study was conducted in order to determine if inhibiting this signalling cascade, which plays a role in the formation and breakdown of cartilage, was able to maintain the integrity of cartilage and prevent further degeneration of the joint. Findings indicated improvements in WOMAC pain and function subscales in all treatment groups, however, patients receiving 0.07mg of the intervention molecule reported increased odds of an OMERACT-OARSI strict response in comparison to the placebo group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
